Abstract

Based on our miRNA expression signatures, we focused on miR-150-5p (the guide strand) and miR-150-3p (the passenger strand) to investigate their functional significance in lung adenocarcinoma (LUAD). Downregulation of miR-150 duplex was confirmed in LUAD clinical specimens. In vitro assays revealed that ectopic expression of miR-150-5p and miR-150-3p inhibited cancer cell malignancy. We performed genome-wide gene expression analyses and in silico database searches to identify their oncogenic targets in LUAD cells. A total of 41 and 26 genes were identified as miR-150-5p and miR-150-3p targets, respectively, and they were closely involved in LUAD pathogenesis. Among the targets, we investigated the oncogenic roles of tensin 4 (TNS4) because high expression of TNS4 was strongly related to poorer prognosis of LUAD patients (disease-free survival: p = 0.0213 and overall survival: p = 0.0003). Expression of TNS4 was directly regulated by miR-150-3p in LUAD cells. Aberrant expression of TNS4 was detected in LUAD clinical specimens and its aberrant expression increased the aggressiveness of LUAD cells. Furthermore, we identified genes downstream from TNS4 that were associated with critical regulators of genomic stability. Our approach (discovery of anti-tumor miRNAs and their target RNAs for LUAD) will contribute to the elucidation of molecular networks involved in the malignant transformation of LUAD.

Highlights

  • Lung cancer accounts for the largest number of cancer-related deaths in the world and its morbidity increases annually [1]

  • According to the Kaplan–Meier overall survival curves using TCGA database, we found that the low expression levels of miR-150-5p and miR-150-3p were associated with poor prognosis in lung adenocarcinoma (LUAD) patients

  • We observed significantly reduced luminescence intensities after transfection with miR-150-3p and the wild-type 3’-untranslated regions (UTRs) of tensin 4 (TNS4) (Figure 4C)

Read more

Summary

Introduction

Lung cancer accounts for the largest number of cancer-related deaths in the world and its morbidity increases annually [1]. Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC) and this type of cancer is the leading cause of cancer-related deaths [2]. The survival rate of lung cancer has increased due to effective treatment strategies, including molecularly-targeted drugs and immune checkpoint inhibitors [3]. The efficacy of treatments for patients with distant metastases is limited, thereby resulting in poor prognosis [2]. In LUAD, metastasis occurs even if the primary tumor is small [4,5]. The prognosis of advanced LUAD patients is poor, with average 5-year survival rates below 20% [6]. Additional research to Cancers 2019, 11, 601; doi:10.3390/cancers11050601 www.mdpi.com/journal/cancers

Objectives
Methods
Findings
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.